These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 19633417)

  • 1. Mutant p53 rescue and modulation of p53 redox state.
    Bykov VJ; Lambert JM; Hainaut P; Wiman KG
    Cell Cycle; 2009 Aug; 8(16):2509-17. PubMed ID: 19633417
    [TBL] [Abstract][Full Text] [Related]  

  • 2. p53 as a hub in cellular redox regulation and therapeutic target in cancer.
    Eriksson SE; Ceder S; Bykov VJN; Wiman KG
    J Mol Cell Biol; 2019 Apr; 11(4):330-341. PubMed ID: 30892598
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PRIMA-1 reactivates mutant p53 by covalent binding to the core domain.
    Lambert JM; Gorzov P; Veprintsev DB; Söderqvist M; Segerbäck D; Bergman J; Fersht AR; Hainaut P; Wiman KG; Bykov VJ
    Cancer Cell; 2009 May; 15(5):376-88. PubMed ID: 19411067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structures of oncogenic, suppressor and rescued p53 core-domain variants: mechanisms of mutant p53 rescue.
    Wallentine BD; Wang Y; Tretyachenko-Ladokhina V; Tan M; Senear DF; Luecke H
    Acta Crystallogr D Biol Crystallogr; 2013 Oct; 69(Pt 10):2146-56. PubMed ID: 24100332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Restoration of wild-type p53 function in human tumors: strategies for efficient cancer therapy.
    Wiman KG
    Adv Cancer Res; 2007; 97():321-38. PubMed ID: 17419952
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Restoring p53-dependent tumor suppression.
    Wang W; Rastinejad F; El-Deiry WS
    Cancer Biol Ther; 2003; 2(4 Suppl 1):S55-63. PubMed ID: 14508081
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The p53 tumor suppressor: a master regulator of diverse cellular processes and therapeutic target in cancer.
    Farnebo M; Bykov VJ; Wiman KG
    Biochem Biophys Res Commun; 2010 May; 396(1):85-9. PubMed ID: 20494116
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological reactivation of mutant p53: from protein structure to the cancer patient.
    Wiman KG
    Oncogene; 2010 Jul; 29(30):4245-52. PubMed ID: 20498645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutant p53 reactivation by small molecules makes its way to the clinic.
    Bykov VJ; Wiman KG
    FEBS Lett; 2014 Aug; 588(16):2622-7. PubMed ID: 24768524
    [TBL] [Abstract][Full Text] [Related]  

  • 10. p53: a guide to apoptosis.
    Meulmeester E; Jochemsen AG
    Curr Cancer Drug Targets; 2008 Mar; 8(2):87-97. PubMed ID: 18336191
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Restoration of wild-type p53 function in human cancer: relevance for tumor therapy.
    Bossi G; Sacchi A
    Head Neck; 2007 Mar; 29(3):272-84. PubMed ID: 17230559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reactivation of mutant p53 by capsaicin, the major constituent of peppers.
    Garufi A; Pistritto G; Cirone M; D'Orazi G
    J Exp Clin Cancer Res; 2016 Sep; 35(1):136. PubMed ID: 27599722
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting mutant p53 for efficient cancer therapy.
    Bykov VJN; Eriksson SE; Bianchi J; Wiman KG
    Nat Rev Cancer; 2018 Feb; 18(2):89-102. PubMed ID: 29242642
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of GRO1 as a critical determinant for mutant p53 gain of function.
    Yan W; Chen X
    J Biol Chem; 2009 May; 284(18):12178-87. PubMed ID: 19258312
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulation of p53 activity by HIPK2: molecular mechanisms and therapeutical implications in human cancer cells.
    Puca R; Nardinocchi L; Givol D; D'Orazi G
    Oncogene; 2010 Aug; 29(31):4378-87. PubMed ID: 20514025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent advances in p53 research and cancer treatment.
    Suzuki K; Matsubara H
    J Biomed Biotechnol; 2011; 2011():978312. PubMed ID: 21765642
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospects for p53-based cancer therapy.
    Stokłosa T; Gołab J
    Acta Biochim Pol; 2005; 52(2):321-8. PubMed ID: 15990917
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The proline-rich domain of p53 is required for cooperation with anti-neoplastic agents to promote apoptosis of tumor cells.
    Baptiste N; Friedlander P; Chen X; Prives C
    Oncogene; 2002 Jan; 21(1):9-21. PubMed ID: 11791172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Restoration of p53 to limit tumor growth.
    Wang W; El-Deiry WS
    Curr Opin Oncol; 2008 Jan; 20(1):90-6. PubMed ID: 18043262
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel cancer therapy by reactivation of the p53 apoptosis pathway.
    Bykov VJ; Wiman KG
    Ann Med; 2003; 35(7):458-65. PubMed ID: 14649328
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.